On September 7, 2022 Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Press release, Avid Bioservices, SEP 7, 2022, View Source [SID1234619149]). Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

Morgan Stanley 20th Annual Global Healthcare Conference
Conference Date: September 12-14, 2022
Fireside Chat Time/Date: 12:55 – 1:25 p.m. Eastern on Wednesday, September 14, 2022
Location: Sheraton New York Hotel; webcast available
To listen to the live webcast of the Morgan Stanley fireside chat, or access the archived webcast, please visit: View Source

On September 7, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that it will present at the following healthcare conferences in September (Press release, UroGen Pharma, SEP 7, 2022, View Source [SID1234619148]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. Annual Global Investment Conference

Tuesday, September 13 at 10:30 a.m. ET
Ladenburg Thalmann Healthcare Conference

Analyst Discussion on Thursday, September 29 at 8:30 a.m. ET
Webcasts of both the H.C. Wainwright & Co. and Ladenburg Thalmann presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

On September 7, 2022 Amgen (NASDAQ:AMGN) reported that it will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) (Free ESMO Whitepaper) at 1:30 p.m. ET on Monday, Sept. 12, 2022 (Press release, Amgen, SEP 7, 2022, View Source [SID1234619147]). David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team, will discuss the data being presented from the LUMAKRAS (sotorasib) CodeBreaK 200 confirmatory Phase 3 study in non-small cell lung cancer and data from the full Phase 1b expansion cohort of LUMAKRAS in combination with Vectibix (panitumumab) in colorectal cancer. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

On September 7, 2022 Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, reported it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time (Press release, Applied DNA Sciences, SEP 7, 2022, https://adnas.com/apdn-to-present-at-h-c-wainwright-24th-annual-global-investment-conference/ [SID1234619146]). The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Applied DNA’s CEO and Chairman of the Board of Directors, Dr. James A. Hayward, will present in person and provide an overview of the Company’s business during the presentation.

To listen to a livestream of the Company’s presentation, please click on the following link to register for the conference: Applied DNA presentation at the H.C. Wainwright 24th Annual Global Investment Conference

On September 7, 2022 NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that its senior management will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, in New York City (Press release, NKMax America, SEP 7, 2022, View Source [SID1234619145]). Please see details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NKGen Biotech will also hold one-on-one investor meetings. To schedule a meeting, please contact your Baird representative.